Immuron Ltd (IMRN) stock

IMRNNasdaqPharmaceutical PreparationsFiscal year ends June 30

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Sep 24, 2026Score 4/30

$0.88−0.03 (-3.52%)

Close on Nov 13, 2026Market cap $7.06MP/E –Yield –

Immuron EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Immuron has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IMRN.

Revenue growth5.9% · median 3.4%

Operating margin-49.9% · median -530.5%

Net margin-47.7% · median -493.0%

Advertisement
300 × 250

See a number that looks wrong?